Literature DB >> 22487069

Outcome of hepatectomy for hepatocellular carcinoma in patients with renal dysfunction.

Takeo Toshima1, Ken Shirabe, Shohei Yoshiya, Jun Muto, Toru Ikegami, Tomoharu Yoshizumi, Yoshihiko Maehara.   

Abstract

OBJECTIVES: There are few reports on the efficacy of hepatectomy for hepatocellular carcinoma (HCC) in patients with renal dysfunction (RD). This study aimed to clarify the validity of hepatectomy for treating HCC in RD patients, and to compare postoperative courses in RD and non-RD patients.
METHODS: The clinical features of 722 HCC patients who underwent curative hepatectomy between 1986 and 2009 were retrospectively reviewed. Seventeen patients (2.4%) with preoperative serum creatinine levels of >2.0 mg/dl were defined as the RD group, and, of these, seven who did not receive preoperative haemodialysis were defined as borderline patients. Clinicopathological characteristics and postoperative outcomes were compared between the RD group (n= 17) and the non-RD group (n= 705). The postoperative courses of borderline patients were reviewed in detail.
RESULTS: Overall survival (P= 0.177) and disease-free survival (P= 0.942) after hepatectomy did not differ significantly between the groups. Incidences of massive ascites (35.3% vs. 14.3%; P= 0.034) and pleural effusion (52.9% vs. 17.6%; P= 0.001), defined as massive effusion (ME), were significantly higher in the RD group than in the non-RD group. Hypoalbuminaemia (≤2.8 g/dl; P= 0.031), heavy blood loss (≥1000 ml; P= 0.012) and intraoperative blood transfusion (P= 0.007) were risk factors for ME. Among the borderline patients, serum creatinine values were not increased immediately after surgery and four patients underwent haemodialysis.
CONCLUSIONS: Preoperative hypoalbuminaemia, heavy blood loss and blood transfusion are independent risk factors for ME in RD patients. Preoperative improvement of anaemia and reduction of blood loss by meticulous surgical techniques may prevent ME in RD patients who require hepatectomy for HCC.
© 2012 International Hepato-Pancreato-Biliary Association.

Entities:  

Mesh:

Year:  2012        PMID: 22487069      PMCID: PMC3384851          DOI: 10.1111/j.1477-2574.2012.00452.x

Source DB:  PubMed          Journal:  HPB (Oxford)        ISSN: 1365-182X            Impact factor:   3.647


  42 in total

1.  Kinetics of hepatitis C virus load and hemodialysis: is there any influence of the reuse of dialysis membrane on HCV viremia?

Authors:  Ronaldo Soares Martins; Olindo Assis Martins Filho; Neiva Sellan Lopes Gonçales; Dora Méndez del Castillo; Luciana Diniz Silva; Luciana Costa Faria; Rosangela Teixeira
Journal:  Scand J Infect Dis       Date:  2011-11-08

2.  Risk factors for massive bleeding during major hepatectomy.

Authors:  Ken Shirabe; Kiyoshi Kajiyama; Norifumi Harimoto; Eiji Tsujita; Shigeki Wakiyama; Yoshihiko Maehara
Journal:  World J Surg       Date:  2010-07       Impact factor: 3.352

Review 3.  Epidemiology, surveillance, and prevention of hepatitis C virus infections in hemodialysis patients.

Authors:  Priti R Patel; Nicola D Thompson; Alexander J Kallen; Matthew J Arduino
Journal:  Am J Kidney Dis       Date:  2010-06-08       Impact factor: 8.860

4.  Incidence and prognosis of different types of functional renal failure in cirrhotic patients with ascites.

Authors:  Silvia Montoliu; Belén Ballesté; Ramon Planas; Marco Antonio Alvarez; Mònica Rivera; Mireia Miquel; Helena Masnou; Isabel Cirera; Rosa Maria Morillas; Susanna Coll; Margarita Sala; Montserrat García-Retortillo; Nuria Cañete; Ricard Solà
Journal:  Clin Gastroenterol Hepatol       Date:  2010-04-24       Impact factor: 11.382

5.  Hepatic aflatoxin B1-DNA adducts and TP53 mutations in patients with hepatocellular carcinoma despite low exposure to aflatoxin B1 in southern Japan.

Authors:  Ken Shirabe; Takeo Toshima; Akinobu Taketomi; Kennichi Taguchi; Tomoharu Yoshizumi; Hideaki Uchiyama; Norifumi Harimoto; Kiyoshi Kajiyama; Akinori Egashira; Yoshihiko Maehara
Journal:  Liver Int       Date:  2011-06-28       Impact factor: 5.828

6.  Overview of regular dialysis treatment in Japan (as of 31 December 2008).

Authors:  Shigeru Nakai; Kazuyuki Suzuki; Ikuto Masakane; Atsushi Wada; Noritomo Itami; Satoshi Ogata; Naoki Kimata; Takashi Shigematsu; Toshio Shinoda; Tetsuo Syouji; Masatomo Taniguchi; Kenji Tsuchida; Hidetomo Nakamoto; Shinichi Nishi; Hiroshi Nishi; Seiji Hashimoto; Takeshi Hasegawa; Norio Hanafusa; Takayuki Hamano; Naohiko Fujii; Seiji Marubayashi; Osamu Morita; Kunihiro Yamagata; Kenji Wakai; Yuzo Watanabe; Kunitoshi Iseki; Yoshiharu Tsubakihara
Journal:  Ther Apher Dial       Date:  2010-12       Impact factor: 1.762

7.  Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension.

Authors:  Elsa Solà; Sabela Lens; Mónica Guevara; Marta Martín-Llahí; Claudia Fagundes; Gustavo Pereira; Marco Pavesi; Javier Fernández; Juan González-Abraldes; Angels Escorsell; Antoni Mas; Jaume Bosch; Vicente Arroyo; Pere Ginès
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

Review 8.  Intrahepatic angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension?

Authors:  Dominique Thabut; Vijay Shah
Journal:  J Hepatol       Date:  2010-07-24       Impact factor: 25.083

9.  Impact of very early high doses of recombinant erythropoietin on anemia and allograft function in de novo kidney-transplant patients.

Authors:  Nassim Kamar; Anne-Hélène Reboux; Olivier Cointault; Laure Esposito; Isabelle Cardeau-Desangles; Laurence Lavayssière; Joëlle Guitard; Hugo Wéclawiak; Lionel Rostaing
Journal:  Transpl Int       Date:  2009-10-09       Impact factor: 3.782

10.  Renal failure in patients with hepatocellular carcinoma and ascites undergoing transarterial chemoembolization.

Authors:  Chia-Yang Hsu; Yi-Hsiang Huang; Chien-Wei Su; Han-Chieh Lin; Jen-Huey Chiang; Pui-Ching Lee; Fa-Yauh Lee; Teh-Ia Huo; Shou-Dong Lee
Journal:  Liver Int       Date:  2009-10-08       Impact factor: 5.828

View more
  6 in total

1.  Hepatic and pancreatic resection in patients with end-stage renal disease: a propensity analysis.

Authors:  Andrew S Barbas; Paul J Speicher; Bryan M Clary
Journal:  HPB (Oxford)       Date:  2014-06-16       Impact factor: 3.647

2.  Hepatic resection for hepatocellular carcinoma patients on hemodialysis for uremia: a nationwide cohort study.

Authors:  Chun-Chieh Yeh; Jaw-Town Lin; Long-Bin Jeng; Iakovidis Charalampos; Tzu-Ting Chen; Teng-Yu Lee; Ming-Shiang Wu; Ken N Kuo; Yi-Ya Liu; Chun-Ying Wu
Journal:  World J Surg       Date:  2013-10       Impact factor: 3.352

3.  Liver Resection for Hepatocellular Carcinoma in Patients with Renal Dysfunction.

Authors:  Chikara Shirata; Kiyoshi Hasegawa; Takashi Kokudo; Suguru Yamashita; Satoshi Yamamoto; Junichi Arita; Nobuhisa Akamatsu; Junichi Kaneko; Yoshihiro Sakamoto; Norihiro Kokudo
Journal:  World J Surg       Date:  2018-12       Impact factor: 3.352

4.  Does Chronic Kidney Disease Really Affect the Complications and Prognosis After Liver Resection for Hepatocellular Carcinoma? A Meta-Analysis.

Authors:  Xiao-Yu Liu; Zhi-Qiang Zhao; Yu-Xi Cheng; Wei Tao; Chao Yuan; Bin Zhang; Chun-Yi Wang
Journal:  Front Surg       Date:  2022-04-06

5.  Impact of comorbid renal dysfunction in patients with hepatocellular carcinoma on long-term outcomes after curative resection.

Authors:  Yuzuru Sakamoto; Shingo Shimada; Toshiya Kamiyama; Ko Sugiyama; Yoh Asahi; Akihisa Nagatsu; Tatsuya Orimo; Tatsuhiko Kakisaka; Hirofumi Kamachi; Yoichi M Ito; Akinobu Taketomi
Journal:  World J Gastrointest Surg       Date:  2022-07-27

Review 6.  Hepatocellular carcinoma in patients with renal dysfunction: Pathophysiology, prognosis, and treatment challenges.

Authors:  Hsuan Yeh; Chung-Cheng Chiang; Tzung-Hai Yen
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.